Discovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis
Journal of Medicinal Chemistry · 09.02.2023 · 66 (3) · 2161-2168
DOI: 10.1021/acs.jmedchem.2c01977 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 19.01.2023. Verfasst von Gebhard Thoma und 13 weiteren Autor:innen. Beteiligte Einrichtung: Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Dermatitis, Atopic. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
The JAK kinases JAK1, JAK2, JAK3, and TYK2 play key roles in cytokine signaling. Activation of the JAK/STAT pathways is linked to many diseases involving the immune system, including atopic dermatitis. As systemic JAK inhibitor pharmacology is associated with side effects, topical administration to the skin has been considered to locally restrict the site of action. Several orally bioavailable JAK inhibitors repurposed for topical use have been recently approved or are in clinical development. Here, we disclose our clinical candidate CEE321, which is a potent pan JAK inhibitor in enzyme and cellular assays. In contrast to repurposed oral drugs, CEE321 does not display high potency in blood and has a high clearance in vivo. Therefore, we consider CEE321 to be a "soft drug". When applied topically to human skin that was stimulated with the cytokines IL4 and IL13 ex vivo, CEE321 potently inhibited biomarkers relevant to atopic dermatitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
- Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
- PK Sciences, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland.
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States.
ORCID-Profile: Gebhard Thoma
Zitieren
APA
Thoma, G., Duthaler, R. O., Waelchli, R., Hauchard, A., Bruno, S., Strittmatter-Keller, U., Orjuela Leon, A., Viebrock, S., Aichholz, R., Beltz, K., Grove, K., Hoque, S., Rudewicz, P. J., & Zerwes, H. G. (2023). Discovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis. Journal of Medicinal Chemistry, 66(3), 2161-2168. https://doi.org/10.1021/acs.jmedchem.2c01977
Vancouver
Thoma G, Duthaler RO, Waelchli R, Hauchard A, Bruno S, Strittmatter-Keller U, et al. Discovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis. Journal of Medicinal Chemistry. 2023;66(3):2161-2168. doi:10.1021/acs.jmedchem.2c01977
BibTeX
@article{Thoma2023,
author = {Thoma, Gebhard and Duthaler, Rudolf O and Waelchli, Rudolf and Hauchard, Alice and Bruno, Sandro and Strittmatter-Keller, Ulrike and Orjuela Leon, Anette and Viebrock, Sabine and Aichholz, Reiner and Beltz, Karen and Grove, Kerri and Hoque, Shaila and Rudewicz, Patrick J and Zerwes, Hans-Guenter},
title = {Discovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {3},
pages = {2161--2168},
doi = {10.1021/acs.jmedchem.2c01977}
}
EUVIMED